ArticleThe Journal of clinical endocrinology and metabolism2020
Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease.
Article in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Statins and thyroid eye disease (TED): a systematic review.Endocrine · 2024Pooled it
- A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.Reviews in endocrine & metabolic disorders · 2022Pooled it
- Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.The Journal of clinical endocrinology and metabolism · 2023Trial
- Clinical outcomes of thyroid function in patients with thyrotropin receptor blocking antibody-positive hypothyroidism.Journal of the Endocrine Society · 2026Article
- ICPi-Induced Graves' Disease with Pre-existing Autoimmune Thyroid Disorders: A Case Report and Literature Review.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Bibliometrics in thyroid eye disease.Journal of endocrinological investigation · 2026Article
- Unravelling the pathogenic mechanisms in Graves' orbitopathy.European thyroid journal · 2025Review
- Microvascular Ultrasonography Vascularity Index as a Rapid and Simplified Assessment Tool for Differentiating Graves' Disease from Destructive Thyroiditis and Managing Thyrotoxicosis.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Thyroid-stimulating immunoglobulin levels during low-dose antithyroid therapy predict Graves' disease relapse.Frontiers in endocrinology · 2025Article
- Amiodarone Therapy: Updated Practical Insights.Journal of clinical medicine · 2024Review
- Prognostic factors for thyroid-stimulating immunoglobulin normalization in moderate-to-severe Graves' orbitopathy: a 36-month longitudinal study.BMC ophthalmology · 2024Article
- Smoking enhances proliferation, inflammatory markers, and immunoglobulins in peripheral blood mononuclear cells from Graves' patients.Endocrine connections · 2024Article
- Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves' orbitopathy.Frontiers in endocrinology · 2024Article
- Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in the diagnosis and management of Graves' disease.Frontiers in endocrinology · 2024Article
- A novel bioassay for thyroid-blocking immunoglobulins.Frontiers in endocrinology · 2024Article
- A TSHR-Targeting Aptamer in Monocytes Correlating with Clinical Activity in TAO.International journal of nanomedicine · 2024Article
- The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves' Disease.Endocrinology and metabolism (Seoul, Korea) · 2023Article
- Traditional Chinese medicine in thyroid-associated orbitopathy.Journal of endocrinological investigation · 2023Review
- A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy.Frontiers in immunology · 2023Review
- Long-Term Outcome of Graves' Disease: A Gender Perspective.Women's health reports (New Rochelle, N.Y.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextScarce data exist regarding the relevance of stimulatory (TSAb) and blocking (TBAb) thyrotropin receptor antibodies in the management of Graves disease (GD).
objectiveTo evaluate the clinical utility and predictive value of TSAb/TBAb.
designProspective 2-year trial.
settingAcademic tertiary referral center. PATIENTS: One hundred consecutive, untreated, hyperthyroid GD patients.
methodsTSAb was reported as percentage of specimen-to-reference ratio (SRR) (cutoff SRR < 140%). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine thyrotropin (TSH, thyroid stimulating hormone) alone (cutoff > 40% inhibition).
main outcome measuresResponse versus nonresponse to a 24-week methimazole (MMI) treatment defined as biochemical euthyroidism versus persistent hyperthyroidism at week 24 and/or relapse at weeks 36, 48, and 96.
resultsForty-four patients responded to MMI, of whom 43% had Graves orbitopathy (GO), while 56 were nonresponders (66% with GO; P < 0.01). At baseline, undiluted serum TSAb but not thyroid binding inhibitory immunoglobulins (TBII) differentiated between thyroidal GD-only versus GD + GO (P < 0.001). Furthermore, at baseline, responders demonstrated marked differences in diluted TSAb titers compared with nonresponders (P < 0.001). During treatment, serum TSAb levels decreased markedly in responders (P < 0.001) but increased in nonresponders (P < 0.01). In contrast, TBII strongly decreased in nonresponders (P = 0.002). All nonresponders and/or those who relapsed during 72-week follow-up period were TSAb-positive at week 24. A shift from TSAb to TBAb was noted in 8 patients during treatment and/or follow-up and led to remission.
conclusionsSerum TSAb levels mirror severity of GD. Their increase during MMI treatment is a marker for ongoing disease activity. TSAb dilution analysis had additional predictive value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.